Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $29.56

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $29.56.

A number of research firms have commented on FDMT. Royal Bank Of Canada lowered their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. The Goldman Sachs Group lowered their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Chardan Capital lowered their price target on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Barclays lowered their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, Bank of America lowered their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, March 10th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BVF Inc. IL raised its position in shares of 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after acquiring an additional 1,890,647 shares in the last quarter. Vanguard Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after acquiring an additional 92,791 shares in the last quarter. Millennium Management LLC raised its position in shares of 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock worth $5,278,000 after acquiring an additional 213,264 shares in the last quarter. Federated Hermes Inc. raised its position in shares of 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after acquiring an additional 1,246,419 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of 4D Molecular Therapeutics by 159.5% in the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after acquiring an additional 504,086 shares in the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Stock Performance

FDMT stock traded down $0.23 during trading on Wednesday, hitting $3.84. 1,440,145 shares of the company traded hands, compared to its average volume of 815,635. The firm has a market capitalization of $177.91 million, a PE ratio of -1.21 and a beta of 2.84. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93. The company has a 50-day moving average of $3.70 and a 200-day moving average of $4.29.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. Sell-side analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.